Menu
Menu
The SOPHiA GENETICS™ Global Precision Medicine Forum returns to ESMO! Join us on October 22nd at 3:00 PM CET at the Novotel Madrid Campo de las Naciones, Madrid, Spain, for its 2026 edition.
The liquid biopsy movement continues. Building on the conversation started by SOPHiA GENETICS and Memorial Sloan Kettering Cancer Center (MSK) at ASCO 2026, this forum explores how expanding access to liquid biopsy is now translating into clinical action. Join the pioneers driving this transformation as they share real-world insights from routine practice, demonstrate how decentralized testing is shaping patient care, and reveal how the same model is enabling the next generation of precision oncology biomarkers.
Join Pharma and Biotech leaders, oncology KOLs, and diagnostic partners to explore The Liquid Biopsy Movement: From Access to Action, and how it is reshaping the future of cancer care.
Across different sessions, the forum will explore:
Don’t miss this unique opportunity and reserve your spot now!
We are delighted to participate in the ESMO AI & Digital Oncology Congress 2026, where you can meet with our Multimodal and BioPharma teams for three exciting days of innovation, networking, and insights into AI-powered solutions and breakthroughs to transform precision oncology.
Join us at booth #11 to:
What began at our inaugural forum in 2024 has since taken shape across the field. SOPHiA GENETICS and the Memorial Sloan Kettering Cancer Center (MSK) return to ASCO to convene leading voices in precision oncology, this time with a singular focus: the liquid biopsy revolution.
This forum traces the journey from a pioneering academic-industry collaboration with MSK to a global movement reshaping how cancer is detected, monitored, and treated.
Topics:
Speakers:
Join SOPHiA GENETICS™ and ARC Regulatory for an exclusive Industry Reception bringing together precision medicine and pharma leaders in Boston on July 21st.
Following our recently announced Master Collaboration Agreement, this event will spotlight our integrated solution for pharma companies across the clinical development lifecycle in Europe, combining ARC's IVDR regulatory expertise with SOPHiA GENETICS' NGS technology and CE-IVD track record.
You’ll hear directly from both teams about key milestones, including the co-development of a Clinical Trial Assay (CTA) designed to accelerate patient recruitment in European clinical trials.
Accelerate with Impact: Expanding Patient Access to Precision Medicine Across the EU
The programme will be followed by a networking reception, offering a unique opportunity to connect with peers and leaders shaping the future of precision medicine.
Reserve your spot today!
We are thrilled to be back at the 16th World Clinical Biomarkers & Companion Diagnostics Summit. Join us and meet our BioPharma team to learn how we help BioPharma companies address challenges throughout the drug development continuum, enhancing efficiency and precision to accelerate the development of better and more effective precision therapeutics.
Our team will be happy to see you join our Plenary Talk and our Co-hosted Engager with Myriad Genetics.
Plenary Talk on Tuesday, October 6th, from 5.40 to 6.10 pm.
“The Power of Modular CGP: Enabling Precision Oncology Across Drug Development”
Mike Berger, PhD, Co-Director, Marie Josee & Henry Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Julien Pontis, PhD, Head of CDx & Clinical Diagnostics, SOPHiA GENETICS
Join this session to explore how MSK-IMPACT® Flex powered with SOPHiA DDM™ is reshaping the future of precision medicine. In this session you will:
Understand how a flexible, future-proof CGP infrastructure helps pharma keep pace with an evolving biomarker landscape, and how SOPHiA GENETICS is already delivering this across the drug development continuum through hands-on partnerships with key diagnostic players.
Co-hosted Engager, coupled with a networking dinner, on Tuesday, October 6th from 7.30 to 10.00 pm.
“Pioneering Precision Medicine: A New Model for CDx Development & Commercialization”
In this workshop, we will explore how a groundbreaking industry collaboration is rethinking current CDx approaches through a hybrid model designed for rapid scalability and access in precision medicine.
This is an invitation-only engager session. If you are interested in attending, please contact the Hanson Wade team.
European Society for Medical Oncology (ESMO) Annual Meeting
SOPHiA GENETICS is excited to be part of the European Society For Medical Oncology (ESMO) Annual Meeting.
You will have the chance to chat with our experts at booth #8068 to discuss our solutions for BioPharma and to demo the universal SOPHiA DDM™ Platform.
Visit us at the Booth and find out how to:
✅ Transform your precision therapy journey with next-generation genomics solutions tailored to your unique requirements
✅ Optimize each stage of drug development with efficient end-to-end Clinical Trial Assay (CTA) and CDx development
✅ Rise above the noise and trust your results with decentralized and best-in-class NGS solutions
✅ Transform oncology data complexity into valuable insights with the power of AI
✅ Streamline your market access strategy by unveiling insights from real-world data
✅ Accelerate global testing adoption and enable sustainable patient access to precision therapies by harnessing the vast global SOPHiA DDM® network
Meet us there!
SOPHiA GENETICS and Myriad Genetics have joined forces in a unique partnership combining Myriad’s centralized CDx and regulatory expertise with SOPHiA GENETICS’ decentralized, data-driven platform.
In this engager we explore how a groundbreaking industry collaboration is rethinking current CDx approaches through a hybrid model designed for rapid scalability and access to precision medicine. Attendees will:
Topics:
Speakers:
Scientific innovation and the unprecedented surge in health data generated every day are transforming our understanding of disease and reshaping the future of precision medicine. As FDA-approved biomarker-targeted therapies continue to expand rapidly, BioPharma companies face increasing pressure to bring them to the market faster to the patients who need them the most. As such, the delivery of robust, accurate, and scalable end-to-end diagnostic solutions across the globe has become essential.
In this talk, we will explore how SOPHiA GENETICS empowers BioPharma to advance precision medicine by harnessing AI-powered analytics and next-generation genomics solutions, improving access to new therapies worldwide and helping close critical health equity gaps.
Speaker:
Jess Lambe, MBA
VP & Managing Director BioPharma Business Development, SOPHiA GENETICS
SOPHiA GENETICS will be at the Association for Molecular Pathology Europe Congress (AMP Europe) 2026 in Tallinn, Estonia. Find us at Booth #13 where our team of experts will be ready to discuss how SOPHiA DDM™ platform is helping laboratories and healthcare institutions advance data-driven oncology insights.
Come explore our partnership with the Memorial Sloan Kettering Cancer Center and our latest updates across the MSK solutions portfolio, including enhanced CNV detection with tumor purity and ploidy analysis in MSK-IMPACT® Flex, and new capabilities in MSK-ACCESS® including MSI and ctDNA fraction, now available on GEN2.
Also learn more about OncoKB™ which is now fully embedded in SOPHiA DDM™ oncology workflows, and what that means for somatic variant interpretation in practice.
Industry Symposium
Join our Industry Symposium to explore how combining MSK-IMPACT® Flex and MSK-ACCESS® on the SOPHiA DDM™ Platform unlocks deeper, more complete oncology insights. From real-world use cases to the latest liquid biopsy enhancements, this is a must-attend session for those looking to take their genomic profiling further.
Monday, 15 June | 2:30pm – 3:30pm | Ballroom
Integrating tissue and liquid biopsy for in-depth precision oncology insights
Dr. Maria De Bonis, Biologist and Health Manager, Fondazione Policlinico A. Gemelli IRCCS, Italy
Lina Li, Product Director of Solid Tumors, SOPHiA GENETICS
The SOPHiA GENETICS™ Global Precision Medicine Forum returns to Chicago! Join us on May 29th at 3:00 PM CST at The Metropolitan in Chicago, IL, for its 2026 edition.
Two years ago, SOPHiA GENETICS and Memorial Sloan Kettering Cancer Center (MSK) started a liquid biopsy revolution that has since grown into a global shift in precision oncology access. This forum brings together the minds behind that shift to reflect on what was built, its real-world impact, and reveal what comes next.
Join Pharma and Biotech leaders, oncology KOLs, and diagnostic partners to explore The Liquid Biopsy Movement: From MSK to the World, and how it is reshaping the future of cancer care.
Across different sessions, the forum will explore:
Don't miss this unique opportunity and reserve your spot now!
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.